Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
Following development candidate validation, Ipsen will assume responsibility for further development and commercialization, leveraging existing neuroscience expertise in movement disorders
- Following development candidate validation, Ipsen will assume responsibility for further development and commercialization, leveraging existing neuroscience expertise in movement disorders
This promising platform technology created by Skyhawk allows for the exploration of previously undruggable RNA targets with small molecules, expanding the disease target landscape1
PARIS, FRANCE; BOSTON, U.S., 22 April 2024 - Ipsen (Euronext: IPN; ADR: IPSEY) and Skyhawk Therapeutics today announced the signing of an exclusive worldwide collaboration to discover and develop novel small molecules that modulate RNA for rare neurological diseases. - The agreement includes an option pursuant to which Ipsen would acquire exclusive license for the worldwide rights to develop successful development candidates (DC).
- Following successful DC nomination, Ipsen will be responsible for all activities.
- Skyhawk’s unique platform accelerates building RNA-targeting small molecules across several therapeutic areas, including rare neurological diseases.2
“We are delighted to join forces with the expert teams at Skyhawk, as we explore the potential for modifying RNA expression across rare and debilitating neurological conditions.” said Steve Glyman, SVP and Head of Neuroscience, Research & Development at Ipsen.